This is a preview of subscription content, log in via an institution to check access.
References
Hart B. Replacing or reducing high dose oral corticosteroids with alternative asthma controller therapies: implications for leukotriene receptor antagonists. Eur Resp Rev 1998; 8: 1056–8
D’Cruz DP, Barnes NC, Lockwood CM. Difficult asthma or Churg-Strauss syndrome? BMJ 1999 Feb 20; 318: 475–6
Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999 Feb 27; 353: 725–6
Barnes N. Replacing or reducing high-dose oral corticosteroids with alternative asthma controller therapies: implications for leukotriene receptor antagonists. Eur Resp Rev 1998; 8: 1054–5
Smith LJ. A risk-benefit assessment of antileukotrienes in asthma. Drug Saf 1998 Sep; 19(3): 205–18
Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999 Jan 2; 353: 57–62
Kinoshita M, Shiraishi T, Koga T, et al. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol 1999 Mar; 103: 534–5
Glaxo Wellcome letter to health care professionals. Reactions 1999 Jan 30; 736: 2
Rights and permissions
About this article
Cite this article
Do antileukotrienes uncover Churg-Strauss syndrome?. Drugs Ther. Perspect 13, 14–16 (1999). https://doi.org/10.2165/00042310-199913100-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199913100-00005